GSTZ1 Antibody

Introduction to GSTZ1 Antibody

The GSTZ1 antibody is a research tool designed to detect and quantify glutathione S-transferase zeta 1 (GSTZ1), a critical enzyme encoded by the GSTZ1 gene located on chromosome 14q24.3 . GSTZ1, also known as maleylacetoacetate isomerase (MAAI), plays dual roles in detoxification (via glutathione conjugation) and intermediary metabolism (tyrosine/phenylalanine catabolism) . Deficiencies in GSTZ1 are linked to metabolic disorders (e.g., alkaptonuria) and cancer progression . Antibodies targeting GSTZ1 enable researchers to study its expression, localization, and functional roles in disease models.

Research Applications and Findings

GSTZ1 antibodies have been instrumental in uncovering the enzyme’s role in disease mechanisms:

Hepatocellular Carcinoma (HCC)

• Tumor Suppressor Role: GSTZ1 deficiency promotes HCC proliferation by activating the NRF2/IGF1R axis, leading to oxidative stress and metabolic dysregulation . Studies using GSTZ1-knockout (KO) models showed increased hepatocarcinogenesis in mice .

• Sorafenib Resistance: Overexpression of GSTZ1 sensitizes HCC cells to sorafenib by enhancing ferroptosis, while KO cells exhibit resistance .

Metabolic Disorders

• GSTZ1 is critical for detoxifying dichloroacetic acid (DCA), preventing hepatotoxicity . Genetic variations (e.g., E32K haplotype) reduce GSTZ1 activity, influencing drug metabolism .

Oxidative Stress Regulation

• Engineered GSTZ1 variants mimic glutathione peroxidase (GPX), offering therapeutic potential against neurodegenerative diseases and atherosclerosis .

Key Research Insights

Clinical and Therapeutic Implications

• Diagnostic Potential: GSTZ1 expression correlates with HCC prognosis; low levels predict poor survival .

• Therapeutic Targets: Inhibiting NRF2 or IGF1R may counteract GSTZ1 deficiency in HCC . Combining sorafenib with ferroptosis inducers (e.g., RSL3) could overcome drug resistance .

Challenges and Future Directions

• Species Cross-Reactivity: Most antibodies are validated for human, mouse, and rat tissues, but cross-reactivity in other models requires further study .

• Functional Variants: Haplotype-specific effects (e.g., KGT, KGM) on GSTZ1 activity necessitate personalized approaches in metabolic therapies .